Together, we can positively impact patients living with atopic dermatitis
Atopic dermatitis (AD) may often be ignored, but no one should look away from the weight that people who are suffering from this condition bear. Use these materials to learn more about atopic dermatitis and possible treatments to help your patients better control it.
Disease Education
The better we understand AD, the better prepared we will all be in helping patients gain control over this condition.
Consensus Recommendations for Optimizing AD Treatment1
Achievement of Minimal Disease Activity (MDA) Through Shared Decision-Making
CONSENSUS RECOMMENDATION:
Patients determine which aspects of their disease are most important or impactful
Clinician then chooses:
- ≥1 clinician-reported measure
- ≥1 patient-reported measure that reflects what is important to the patient
Achievement of BOTH clinician and patient
agreed-upon “optimal” targets is defined as MDA.
Treatment response may be considered inadequate if agreed-upon targets are not met within 3–6 months.
| Clinician-Reported Outcome Measures | Optimal Target |
|---|---|
| EASI | EASI 90 or EASI ≤3 |
| SCORAD | SCORAD 75 or SCORAD ≤10 |
| IGA and BSA | IGA 0/1 and BSA ≤2% |
| Patient-Reported Outcome Measures | Optimal Target |
|---|---|
| If itch chosen, use peak pruritus NRS | ≤1 |
| If skin appearance/condition chosen, use POEM | ≤2 |
| If sleep disturbance chosen, use sleep NRS | ≤1 |
| If mental health chosen, use HADS | HADS-A <8 and HADS-D <8 |
| If skin pain chosen, use pain NRS | ≤1 |
| If impact on daily life chosen, use DLQI (>16 yrs), CDLQI (4–16 yrs), or IDQOL (<4 yrs) | 0/1 |
Proportion of Patients Reporting Optimal DLQI and Sleep Outcomes When Achieving Complete or Almost Complete Skin Clearance (IGA 0/1)2
Among Patients Who Achieved Complete or Almost Complete Skin Clearance (IGA 0/1), DLQI and Sleep Outcomes When They Also Achieve Little or No Itch (WI-NRS 0/1)2
References: 1. Silverberg JI, et al. Combining treat-to-target principles and shared decision-making: international expert consensus-based recommendations with a novel concept for minimal disease activity criteria in atopic dermatitis. J Eur Acad Dermatol Venereol. Published online July 11, 2024. doi:10.1111/jdv.20229 2. Silverberg JI, et al. Greater levels of itch relief and skin clearance correlate with improved patient outcomes in atopic dermatitis–real-world insights from TARGET-DERM AD. Br J Dermatol. 2024;191(suppl 2):ii86-ii87.
Explore our videos below to learn more about atopic dermatits
Treatment Considerations
You and your patients have many treatment options—such as phototherapy, topicals, and systemic therapies—to consider for AD. Take a look at information that may help with your treatment considerations.
Patient Stories
Watch this patient story to gain a deeper understanding of how a life can be changed by AD.
Each shade of skin deserves care
Watch and learn from leading clinical experts on how we can improve dermatologic care for patients of color living with AD.